Pharmaceuticals & Therapeutics

As Angel Yeast marks 40 years, its latest sustainability report reveals a strategic pivot towards biotech and ESG, setting a new industry standard.

U.S. hospitals waste billions in usable medication each year. A new partnership shows how AI and a digital marketplace can plug the leak, a crucial move in an era of drug shortages.

Australian biotech Gelteq has a gel that makes bitter medicine taste good to dogs. It's more than a pet owner's dream—it's a strategic move in a $47B market.

A silent barrier in diabetes care, 'clinical inertia,' leaves patients at risk. New research shows how empowering pharmacists with targeted education can turn the tide.

How one imaging company is challenging sports photography norms by investing in the creator economy and the powerful stories hidden beyond the final score.

Xeris Biopharma secures a new patent for its rare disease drug KEVEYIS until 2039, a strategic move to fend off generic competition and lock in revenue.

Leveraged finance titans turned a personal fight into a philanthropic powerhouse, raising a record $4.3M to fund the science that’s turning the tide on melanoma.

Wellness brands often struggle to turn concepts into viable products. A Utah-based CDMO's new PhD-led center is bridging the gap from science to scale.

A prestigious award for a US defense firm in the Netherlands is more than a ceremony; it's a sign of a new era in transatlantic security and space sovereignty.

A projected 14.9% CAGR signals a gold rush in Alzheimer's agitation treatment. New, safer drugs are replacing risky antipsychotics, offering hope to millions.

With a massive Walmart and CVS launch, Mineral Ice Extreme isn't just selling a new gel; it's executing a classic CPG playbook to challenge giants.

Vivos Therapeutics' unusual rights offering isn't a simple plea for cash. It's a bold wager on its own turnaround and a case study in small-cap survival.

Herbs, Etc. just won Superfood of the Year. We explore how a legacy brand uses 57 years of integrity to innovate and thrive in today's crowded market.

As summer heat strains Tulsa foundations, a local business initiative highlights the growing risk of hidden slab leaks, a costly problem rooted in local geology.

After teetering on the brink, AeroFarms' acquisition by a patient investor signals a crucial shift for the entire vertical farming sector, from VC hype to profitability.

Stunning head-to-head trial data shows Takeda's zasocitinib is 2.5x more effective than its rival, signaling a major market disruption and validating a landmark deal.

With Thomas Winstanley at the helm, Edibles.com eyes dominance in the wellness-THC space. Can his CPG playbook conquer a booming but volatile market?

Relmada Therapeutics poaches a Sage neurosteroid expert for its sepranolone program. A look at the strategic rationale behind a move that signals big ambitions.

Sun Life's Jacques Goulet brings a background in risk management and a proven record of philanthropic impact to his new role as Chair of the MHIF.

A record $1.3B IPO, a minister's endorsement, and a new $75M fund. Apotex's TSX debut isn't just a corporate win; it's a national strategy in motion.